Our study was conducted in cell line model of osteosarcoma, therefore, further preclinical and clinical studies are warranted to evaluate MMP‐2 inhibitors as potential adjuvants to chemotherapy in osteosarcoma. This evidence concerns the gene MMP2 and osteosarcoma.